Johnson & Johnson Files New Trademark and Makes $14.6 Billion Acquisition

Jan/13/2025

On January 7, Johnson & Johnson filed a new trademark application for 'ICOTYDE', signaling its continued focus on innovative treatments for a wide range of diseases, from auto-immune to central nervous system disorders. In tandem, the healthcare giant announced its $14.6 billion acquisition of Intra-Cellular Therapies, securing a critical position in the market for neurological therapies and furthering its aggressive growth strategy through high-value investments.

Johnson & Johnson’s recent U.S. trademark filing for 'ICOTYDE' reflects the company’s ambitions to address a broad spectrum of medical needs. The trademark, covering pharmaceutical preparations for conditions such as autoimmune, inflammatory, cardiovascular, and central nervous system diseases, underscores J&J’s commitment to developing groundbreaking treatments. This move aligns with the company’s strategy to innovate across diverse therapeutic areas, ensuring a robust pipeline in competitive healthcare markets. The new trademark strengthens J&J’s positioning as a leader in providing targeted solutions for complex and chronic illnesses. The following visualization provides detailed information on Johnson & Johnson’s recent trademark filings.

In a transformative deal, Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, paying $132 per share—a 39% premium over its prior closing price. This acquisition grants J&J access to Caplyta, the only U.S.-approved drug for depression linked to bipolar disorder and schizophrenia, further solidifying its foothold in the neurological disorder market. Intra-Cellular, rooted in Nobel Prize-winning research, brings cutting-edge insights into cell-based therapies for psychiatric and neurological conditions. The transaction aligns with J&J’s broader acquisition strategy, which includes recent high-profile purchases like Shockwave Medical and Numab, as the company prepares for post-2025 growth amidst increasing competition for key products like Stelara. The following chart highlights the sales forecast for the world’s leading 10 pharmaceutical companies in 2028 (in billion U.S. dollars), emphasizing the industry’s expansive growth and J&J’s prominent position within it.